Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $3.5 million.

  • Palisade Bio's Total Current Liabilities rose 2972.77% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 2972.77%. This contributed to the annual value of $3.2 million for FY2024, which is 2513.53% up from last year.
  • Per Palisade Bio's latest filing, its Total Current Liabilities stood at $3.5 million for Q3 2025, which was up 2972.77% from $4.0 million recorded in Q2 2025.
  • Palisade Bio's Total Current Liabilities' 5-year high stood at $4.0 million during Q2 2025, with a 5-year trough of $1.0 million in Q1 2021.
  • Over the past 5 years, Palisade Bio's median Total Current Liabilities value was $2.8 million (recorded in 2024), while the average stood at $2.7 million.
  • As far as peak fluctuations go, Palisade Bio's Total Current Liabilities skyrocketed by 46954.68% in 2021, and later crashed by 2945.28% in 2023.
  • Over the past 5 years, Palisade Bio's Total Current Liabilities (Quarter) stood at $2.9 million in 2021, then increased by 3.15% to $3.0 million in 2022, then fell by 14.14% to $2.6 million in 2023, then increased by 25.14% to $3.2 million in 2024, then grew by 7.48% to $3.5 million in 2025.
  • Its Total Current Liabilities stands at $3.5 million for Q3 2025, versus $4.0 million for Q2 2025 and $2.8 million for Q1 2025.